glp-1 obesity drug news oct 21 2025 Drugmakers are racing to find the next Wegovy. These trials are ones to watch CVS obesity drug deal puts
Description
1 In a recent Kaiser Family Foundation poll of adults living in the United States, 43% of individuals diagnosed with diabetes responded that they had taken a GLP-1/GIP agonist at one point in time
Thioreductase-containing epitopes inhibit the development of type 1 diabetes in the NOD mouse model
Interestingly, Gabery et al
doi: 10.2337/dbi20-0002
Ascletis isn't the only company chasing depot technology
